Genetic Alteration Burden

Genetic Alteration Burden is a quantitative measure of the total number of genetic alterations, most commonly somatic mutations, present within the genome of a tumor, typically expressed as a count normalized to the amount of genomic sequence examined. This measure provides a summary metric of how heavily a cancer genome has been altered relative to the normal, non-cancerous genome from which it arose.

Measuring Genetic Alteration Burden

Tumor Mutational Burden

The most widely used expression of alteration burden is tumor mutational burden, defined as the number of somatic mutations detected per megabase of genomic sequence analyzed. This normalization allows comparison of mutation counts across tumors regardless of how much of the genome or exome was sequenced.

Copy Number Burden

Beyond point mutations, alteration burden can also refer to the extent of copy number changes across a tumor genome, capturing how much of the genome has been affected by gains, losses, or other structural rearrangements relative to the normal diploid state.

Structural Variant Burden

Some tumors are characterized less by point mutation accumulation and more by extensive structural rearrangement, including translocations, inversions, and complex chromosomal reshuffling events, contributing an additional dimension to overall alteration burden beyond simple mutation counts.

Sources of Variation in Alteration Burden

Mutagen Exposure

Tumors arising in tissues chronically exposed to strong mutagens, such as skin exposed to ultraviolet radiation or lung tissue exposed to tobacco smoke, tend to accumulate substantially higher mutation burdens than tumors arising in tissues without comparable exposure history.

DNA Repair Deficiency

Defects in DNA repair pathways, particularly deficiencies in mismatch repair, dramatically elevate mutation burden by allowing replication errors to persist uncorrected, producing tumors with mutation burdens far exceeding those of repair-proficient cancers of the same type.

Tissue of Origin

Different cancer types show characteristic ranges of alteration burden even in the absence of unusual mutagen exposure or repair defects, reflecting differences in the normal replication history, cell turnover rate, and baseline mutational processes active in different tissues.

Tumor Stage and Evolutionary History

Because mutations continue to accumulate as a tumor grows and divides over time, alteration burden can increase as a tumor progresses, though the relationship between burden and disease stage varies considerably across cancer types.

Biological Consequences of High Alteration Burden

Neoantigen Generation

A higher mutation burden increases the likelihood that some mutations will alter protein sequences in a way that generates new, tumor-specific peptides capable of being recognized by the immune system as foreign, known as neoantigens.

Genomic Instability

Extremely high alteration burden often reflects an underlying state of pervasive genomic instability, in which the normal mechanisms maintaining genome fidelity have been substantially compromised, allowing errors to accumulate largely unchecked.

Clinical Applications

Immunotherapy Response Prediction

Tumors with high mutational burden are more likely to produce abundant neoantigens capable of stimulating an anti-tumor immune response, and elevated tumor mutational burden has been used as a biomarker to help identify patients more likely to benefit from therapies that enhance immune recognition of cancer cells.

Identifying Repair Deficiency

An unusually high alteration burden in a tumor that would not otherwise be expected to show heavy mutagen exposure can prompt further investigation into an underlying DNA repair deficiency, which may itself carry independent therapeutic implications.

Prognostic Considerations

The relationship between alteration burden and clinical outcome varies by cancer type and treatment context, meaning that burden alone is generally interpreted alongside other genomic and clinical features rather than as an isolated prognostic measure.

Measurement Considerations

Accurate assessment of alteration burden depends on consistent sequencing depth, appropriate filtering to exclude sequencing artifacts and germline variants, and standardized normalization methods, since technical differences between sequencing platforms and analysis pipelines can otherwise produce inconsistent burden estimates for the same underlying tumor.